Protagonist Therapeutics Overview
Protagonist Therapeutics Target Price
Analysts' 12-month price predictions for PTGX.
Get informed when a big investor buys or sells
+ FollowShare Price
$131.62
Average Target Price
$117.33
10.9% downside
10.9% downside3 analysts in the last 4 months
High: $121 | Low: $110
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-05-06 | Goldman Sachs | $110 | 16.4% downside |  |
| 2026-04-14 | Truist FinancialSrikripa Devarakonda | $121 | 8.1% downside | |
| 2026-03-18 | JefferiesRoger Song | $121 | 8.1% downside | |
| 2026-01-30 | H.C. Wainwright | $117 | 11.1% downside | |
| 2026-01-05 | Truist Financial | $110 | 16.4% downside | |
| 2025-12-17 | Barclays | $108 | 17.9% downside | |
| 2025-10-28 | Truist FinancialSrikripa Devarakonda | $88 | 33.1% downside | |
| 2025-10-13 | Johnson Rice | $112 | 14.9% downside | |
| 2025-10-07 | Johnson Rice | $74 | 43.8% downside | |
| 2025-09-16 | Barclays | $72 | 45.3% downside | |
| 2025-03-11 | Wedbush | $70 | 46.8% downside | |
| 2025-03-11 | Truist Financial | $76 | 42.3% downside | |
| 2025-03-03 | BTIG | $73 | 44.5% downside | |
| 2024-12-05 | BMO CapitalEtzer Darout | $62 | 52.9% downside | |
| 2024-11-22 | Truist FinancialSrikripa Devarakonda | $60 | 54.4% downside | |
| 2024-09-12 | H.C. WainwrightDouglas Tsao | $50 | 62% downside | |
| 2024-06-17 | H.C. WainwrightDouglas Tsao | $38 | 71.1% downside | |